Brim Biotechnology upholds the principles of integrity, transparency, and professionalism, with the Board of Directors serving as the highest governance body responsible for overseeing corporate development, operations, and strategic planning. Under the Board are the Audit Committee and the Compensation Committee, which, through a clear division of responsibilities and professional specialization, assist in strengthening the Board’s functions and establishing a sound corporate governance framework.
Board Diversity
In accordance with the Company’s Articles of Incorporation, the Board of Directors shall consist of five to nine members serving a three-year term, and directors are elected through a candidate nomination system.
The members of the Board are distinguished professionals from various industries and management fields, possessing extensive experience in finance, business management, and new drug development. In compliance with relevant laws, the Articles of Incorporation, and resolutions of the shareholders’ meeting, the Board fulfills its duties by formulating the Company’s operational policies, overseeing management performance, and safeguarding the rights and interests of stakeholders, while maximizing shareholder value.
Implementation of Board Diversity Policy
Board Performance Evaluation Report
Operations Status:
| Title | Name | Attendance(in person) | Attendance by Proxy | Attendance Rate (%) | Remarks |
| Chairman of the Board | Andrew Lin | 5 | 0 | 100% | 5 meetings in total |
| Vice Chairman | Haishan Jang | 5 | 0 | 100% | 5 meetings in total |
| Director | Affinity Linited Partnership Fund one | 5 | 0 | 100% | 5 meetings in total |
| Director |
Isaiah Capital LLC |
5 | 0 | 100% | 5 meetings in total |
| Director |
CIDC Consultants |
5 | 0 | 100% | 5 meetings in total |
| Director | Audrey Tseng | 5 | 0 | 100% | 5 meetings in total |
| Independent Directors | Johnsee Lee | 5 | 0 | 100% | 5 meetings in total |
| Independent Directors | Howard Kuo | 5 | 0 | 100% | 5 meetings in total |
| Independent Directors | James Cheng | 5 | 0 | 100% | 5 meetings in total |
The important resolutions of the Board of Directors for the year 2025 (as of September 23, 2025) are as follows:
| Meeting Title and Date | Major Resolutions |
|---|---|
| 6th Term, 15th Board Meeting March 14, 2025 | 1. Approval of the 2024 Business Report and Financial Statements.
2. Approval of the 2024 Internal Control System Statement. 3. Acknowledgment of accumulated losses reaching one-half of paid-in capital. 4. Approval of the 2024 Loss Appropriation Proposal. 5. Resolution to convene the 2025 Annual General Shareholders’ Meeting. 6. Approval of the “2025 First Employee Stock Option Issuance and Subscription Procedures.” 7. Approval of the “2025 First Restricted Stock Award Issuance Procedures.” 8. Approval of amendments to the Company’s Articles of Incorporation. 9. Approval of 2025 Incentive Bonus Distribution. 10. Review of the Salary Management Policy and Compensation Structure. 11. Recommendation for Managerial Compensation Adjustments for 2025. 12. Approval to release the Chairman from the non-compete restriction. |
| 6th Term, 16th Board Meeting May 6, 2025 | 1. Appointment and remuneration of certified public accountants for 2025.
2. Approval of the Company’s Q1 2025 Financial Statements. 3. Revision of the “Operational Improvement Plan.” 4. Granting of the 2025 First Employee Stock Options. |
| 6th Term, 17th Board Meeting August 5, 2025 | 1. Approval of the Company’s Q2 2025 Financial Statements.
2. Approval of new share issuance for employee stock option execution and determination of the record date for capital increase. |
